Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306197 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL11845673 | 0.84 | — | — | |
| SCHEMBL28065144 | 0.81 | ALDH1A1 (0.35) | — | |
| SCHEMBL11531912 | 0.81 | ALDH1A1 (0.35) | LMNA | |
| SCHEMBL11142350 | 0.79 | ALDH1A1 (0.46) | LMNA | |
| SCHEMBL23047083 | 0.75 | — | — | |
| SCHEMBL4674255 | 0.75 | — | — | |
| SCHEMBL29098232 | 0.74 | — | — | |
| SCHEMBL28994642 | 0.74 | NOTUM (0.33) | NOTUMLMNAMTNR1AMTNR1B | |
| SCHEMBL9238409 | 0.74 | HTR2B (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174932-B1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2021-06-09 | — | — | EP | claimed |
| US-9969863-B2 | Cure accelerators for anaerobic curable compositions | Henkel IP & Holding GmbH (DE) | 2018-05-15 | — | — | US | claimed |
| US-20170137606-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL AG & CO. KGAA (DE) | 2017-05-18 | — | — | US | claimed |
| CN-114423739-B | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114514223-B | Process for enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines comprising using novel iridium catalysts | 拜耳公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-111902399-B | Enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts | 拜耳公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-114514223-A | Process comprising enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines using a novel iridium catalyst | 拜耳公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114423739-A | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3174932-B1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2021-06-09 | — | — | EP | disclosed |
| CN-111902399-A | Enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts | 拜耳公司 | 2020-11-06 | — | — | CN | disclosed |
| WO-2018150347-A1 | COMPOUNDS WITH BETA-ADRENERGIC AGONIST AND ANTIMUSCARINIC ACTIVITY | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-08-23 | — | — | WO | disclosed |
| WO-2016018553-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2016-02-04 | — | — | WO | disclosed |
| US-9199915-B2 | Process for preparing substituted biphenyls by C-H activation | BAYER CROPSCIENCE AG (DE) | 2015-12-01 | — | — | US | disclosed |
| US-20150203440-A1 | PROCESS FOR PREPARING SUBSTITUTED BIPHENYLS BY C-H ACTIVATION | BAYER CROPSCIENCE AG (DE) | 2015-07-23 | — | — | US | disclosed |
| EP-2880013-A1 | PROCESS FOR PREPARING SUBSTITUTED BIPHENYLS BY C-H ACTIVATION | Bayer CropScience AG (DE) | 2015-06-10 | — | — | EP | disclosed |
| WO-2014019995-A1 | PROCESS FOR PREPARING SUBSTITUTED BIPHENYLS BY C-H ACTIVATION | BAYER CROPSCIENCE AG (DE) | 2014-02-06 | — | — | WO | disclosed |
| EP-1940819-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007022280-A1 | PHOSPHODIESTERASE 10 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | NOTUM 406/4885LMNA 4307/4885MTNR1A 2702/4885 |
| US-20170137606-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | AHCY, AHCYL1, MGMT | NOTUM 2204/4885LMNA 3159/4885MTNR1A 3236/4885 |
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | PDE5A, PDE3A, PDE2A | NOTUM 535/4885LMNA 1512/4885MTNR1A 1410/4885 |
| US-20150203440-A1 | PROCESS FOR PREPARING SUBSTITUTED BIPHENYLS BY C-H ACTIVATION | CYP1A1, CBR1, AHR | NOTUM 2166/4885LMNA 3277/4885MTNR1A 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.